Blockers header.jpg

Blockers

Blockers from BBI Solutions 

We offer an extensive range of assay development and electrophoresis reagents with established performance in enhancing signal through suppression of non-specific binding. 

BBI Solutions offers a range of protein and non-protein based reagents designed to enhance sensitivity of IVD assays by minimising background in IVD assay and electrophoresis blotting applications. Materials are provided as ready to use formulations in specific buffered matrix designed for optimal performance. Bulk components are also offered for specific applications. 

Please contact our Customer Services Team directly to discuss your requirements on tel:+44 (0) 1495 363000 or alternatively you can submit an enquiry here.

Related Products

If you require any further product specific technical information or datasheets please submit your request to our technical team here 

Blockers applications

BBI offers the Surmodics brand range of blocking solutions, designed primarily for use in electrophoresis Western blot applications, to our EU clients. These materials have been designed in buffered solutions that prevent non-specific molecules binding to active surfaces after primary antibodies have been coated. The specific blocker most suited to the application can be determined by experiment. The materials may have additional applicability as blocking reagents in IVD assay design, specifically lateral flow. 

BBI also offers a bulk modified Casein powder as a component for the preparation of bespoke blocking reagents especially for lateral flow applications that can be made available to all clients worldwide.  

 

Technical Documents

If you require any further product specific technical information or datasheets please submit your request to our technical team here 

Request a callback

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox